Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,104.00
(
-0.38%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.50
(
1.84%
)
Bitcoin
78,109.21
(
-0.16%
)
News Focus
News Focus
Post# of 257438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 249417

Thursday, 03/21/2024 12:34:50 PM

Thursday, March 21, 2024 12:34:50 PM

Post# of 257438
TRML—(-36%)—suffers collateral damage_from Roche’s Enspryng trial:

https://www.fiercepharma.com/pharma/despite-positive-trial-roche-says-enspryng-fell-short-expectations-myasthenia-gravis

TRML’s TOUR006 has the same anti-IL-6 MoA as Enspryng.

TRML is the result of a 2023 reverse-merger (#msg-173043164).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today